Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1; no user-visible changes to page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T09:14:55.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Added glossary toggle options (Show glossary / Hide glossary) and minor metadata label changes (capitalization and revision/version update from v3.3.4 to v3.4.0) that do not affect the study's core content.
    Difference
    0.2%
    Check dated 2026-01-22T17:48:28.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no study data, eligibility criteria, or locations appear to be affected.
    Difference
    0.0%
    Check dated 2026-01-15T10:45:06.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Locations section updated with new site entries across multiple US states (Arizona, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New York, Oregon, Texas, Washington) and international regions (Emilia-Romagna, Lazio, Lombardy, Barcelona); some previously listed locations were removed.
    Difference
    1.0%
    Check dated 2025-12-17T20:08:14.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    A note that publications are automatically filled from PubMed was added, and the revision label updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-26T08:31:45.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    The page no longer displays a government funding status notice. Core trial details, enrollment status, eligibility criteria, and location information remain unchanged.
    Difference
    0.2%
    Check dated 2025-11-19T09:17:56.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.